HSBC Mutual Fund has launched the RedHex Hybrid Long-Short Fund, a Specialised Investment Fund (SIF) strategy aimed at investors seeking regular returns along with long-term capital appreciation. The New Fund Offer (NFO) opened on June 2 and will remain available for subscription until June 16, 2026. The fund combines investments across multiple asset classes, including fixed income, equity arbitrage, REITs and INVITs, with the objective of generating risk-adjusted returns across different market cycles. The strategy is benchmarked against the NIFTY 50 Hybrid Composite Debt 50:50 Index.
HSBC Mutual Fund said the product is designed for “mid-ticket” investors and requires a minimum investment of ₹10 lakh, while accredited investors can participate with a minimum investment of ₹1 lakh. The launch comes as SIFs gain traction as an investment category positioned between traditional mutual funds and higher-ticket investment products such as Portfolio Management Services (PMS) and Alternative Investment Funds (AIFs). Kailash Kulkarni, CEO of HSBC Mutual Fund, said the fund offers a balanced solution for investors looking for professional management, lower volatility and tax-efficient risk-adjusted returns. Shriram Ramanathan, CIO – Fixed Income, said the strategy focuses on strong credit selection, risk controls and selective exposure to growing asset classes such as REITs and INVITs.
In Guwahati, wealth advisors and high-net-worth investors in the city are increasingly exploring diversified investment products beyond conventional mutual funds and fixed deposits. Industry observers believe products such as SIFs could attract interest from affluent investors in Guwahati seeking stable income opportunities, portfolio diversification and professionally managed investment solutions amid evolving market conditions. Structured as an interval investment fund, the RedHex Hybrid Long-Short Fund allows subscriptions on any business day and provides weekly redemption opportunities, backed by active portfolio management and stringent risk controls.